A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab

• High-risk multi-agent drug resistant GTN is a life threatening disease. • Majority of choriocarcinomas show intense PD-L1 immunoreactivity. • Pembrolizumab increases antitumor activity. • Effectiveness of Pembrolizumab in treating patients with high-risk multi-agent drug resistant GTN.

Detalles Bibliográficos
Autores principales: Goldfarb, Jennifer A., Dinoi, Giorgia, Mariani, Andrea, Langstraat, Carrie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210394/
https://www.ncbi.nlm.nih.gov/pubmed/32395603
http://dx.doi.org/10.1016/j.gore.2020.100574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210394/
https://www.ncbi.nlm.nih.gov/pubmed/32395603
http://dx.doi.org/10.1016/j.gore.2020.100574

Ejemplares similares